Why 2020 Is Pivotal for Microbiome Drug R&D (Or Maybe 2021, Given COVID-19)
Xconomy
APRIL 22, 2020
Given the number of late-stage and mid-stage studies expected to report data in 2020—assuming they stay on track amid the COVID-19 pandemic—this could be a pivotal year for the field, said Isabelle de Cremoux, CEO and managing partner of Seventure Partners.
Let's personalize your content